Study of role of serum magnesium in preventing carotid atherosclerosis in chronic kidney diseases patients
DOI:
https://doi.org/10.18203/2349-3933.ijam20231075Keywords:
Magnesium, Carotid Intima-media thickness, Cardiovascular mortality, Chronic kidney diseasesAbstract
Background: Cardiovascular diseases are the most important causes of mortality and morbidity in CKD mainly due to accelerated atherosclerosis. Mg2+ possesses an anti-atherosclerotic effect, because of its anti-inflammatory and antioxidant properties, by inhibiting endothelial proliferation and inhibiting the upregulation of PAI 1 and VCAM 1. Mg2+ deficiency promotes hydroxyapatite formation and calcification of VSMC thus leading to accelerated plaque formation. Aim and objectives of current study were to evaluate relationship between serum Mg2+ level and atherosclerotic changes in patients with CKD.
Methods: This hospital based observational cross-sectional study has been carried out in department of KPS institute of medicine, GSVM Medical College, Kanpur. 58 subjects were recruited and underwent routine tests including Serum urea, creatinine, calcium, phosphorus, iPTH, Magnesium and intima media thickness (IMT) of carotid artery via Doppler study.
Results: In our study the mean value of Mg2+ was 2.25 mg/dl±0.81 17 out of 58 patients (29.3%) had hypomagnesemia. Intima Media thickness of carotid artery had an observed mean value of 1.0 cm±0.24, with mostly increased in those who had hypomagnesemia. Serum Mg2+ was negatively correlated (Pearson correlation coefficient was -0.677 and -0.704) with CIMT with statistical significance as p<0.001. Also, our study revealed no significant correlation between serum Mg2+ and other laboratory data (Ca2+, P, iPTH, urea and creatinine.
Conclusions: We concluded that serum Mg2+ may be considered as a modifiable risk factor of atherosclerosis (thus, cardiovascular mortality) in CKD patients.
References
Hsu C, McCulloch C, Iribarren C. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;1:42-9.
Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res. 2007;20(4):237-44.
Kakadiya J. Causes, symptoms, pathophysiology and diagnosis of atherosclerosis- a review. Pharmacol J. 2009;21:14-9.
Turgut F, Kanbay M, Metin M, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis, Int Urol Nephrol. 2008;40:1075-82.
Delucchi A, Dinamarca H, Gainza H, Whitttle C, Torrealba I, Iñiguez G. Carotid intimamedia thickness as a cardiovascular risk marker in pediatric end-stage renal disease patients on dialysis and in renal transplantation. Transplant Proc. 2008;3:23-9.
Delucchi A, Dinamarca H, Gainza H, Whitttle C, Torrealba I, Iñiguez G. Carotid intimamedia thickness as a cardiovascular risk marker in pediatric end-stage renal disease patients on dialysis and in renal transplantation. Transplant Proc. 2008;24:32-8.
Ali Y, Abdel-Latif A, El-Koumi M, Ghorab A, Labib H. Bone activity biomarkers and bone mineral density in children with chronic kidney disease. Arab J Nephrol Transplant. 2010;3:25.
Kanbay M, Goldsmith D, Uyar M, Turgut F, Covic A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010;23:34-8.
Covic A. Magnesium in chronic kidney disease more than just phosphate binding. Europ Nephrol. 2010;32: 12-9.
Yorifuji M, Kuragano T, Kawada S, Fukao W, Toyoda K, Nakanishi T. Factors associated with serum magnesium and vascular stiffness in maintenance hemodialysis patients. Int Soc Hemodial. 2007;23:65-9.
Apetrii M, Covic A, Massy ZA. Magnesium supplementation: A consideration in dialysis patients. Europ Nephrol. 2018;31:23-8.
Parati G, Ochoa J, Bilo G, Agarwal R, Covic A. Hypertension in chronic kidney disease part 1 out-of-office blood pressure monitoring: methods, thresholds, and patterns. Blood Purif. 2006;12:45-8.
Ali T, Genina A, Abo-Salem O. The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients. Benisuef Univ J Basic Applied Sci. 2004;23:31-8.
Sliem H, Tawfik G, Moustafa F. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: A case control study. Indian J Endocr Metab. 2011;23: 32-8.
Ali Y, Abdel-Latif A, El-Koumi M, Ghorab A, Labib H. Bone activity biomarkers and bone mineral density in children with chronic kidney disease. Arab J Nephrol Transplant. 2010;12:43-7.
Chutia H and Abraham A. Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease. J Lab Physician. 2013;23:42-7.
Spiegel D, Gallant KM. Calcium balance in chronic kidney disease. Arab J Nephrol Transplant. 2016;12:32.
Van de Wal-Visscher E, Kooman, Van der Sande F. Magnesium in Chronic Kidney Disease: Should We Care?. Blood Purif. 2018;23:12-9.
Khatami M, Mirchi E, Khazaeipour Z, Abdollahi A, Jahanmardi A. Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. Iran J Kidney Dis. 2013;32:56-9.
Ari E, Kaya Y, Demir H, Asicioglu E, Keskin S. The correlation of serum trace elements and heavy metals with carotid artery atherosclerosis in maintenance hemodialysis patients. Biol Trace Elem Res. 2011;12:41-6.
